Phase I study of pazopanib in combination with weekly paclitaxel in patients with advanced solid tumors

Oncologist

Volumn 15, Issue 12, 2010, Pages 1253-1261

  Tan, Antoinette R ^a   Dowlati, Afshin ^b   Jones, Suzanne F ^c   Infante, Jeffrey R ^c   Nishioka, Jennifer ^a   Fang, Lei ^d   Hodge, Jeffrey P ^d   Gainer, Shelby D ^d   Arumugham, Thangam ^d   Benjamin Suttle, A ^d   Dar, Mohammed M ^d   Lager, Joanne J ^d   Burris III, Howard A ^c  

^a RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c SARAH CANNON RESEARCH INSTITUTE   (United States)

^d GLAXOSMITHKLINE   (United States)

Author keywords

Paclitaxel; Pazopanib; Vascular endothelial growth factor receptor tyrosine kinase inhibitor

Indexed keywords

CYTOCHROME P450 2C8; CYTOCHROME P450 3A4; DEXAMETHASONE; DIPHENHYDRAMINE; PACLITAXEL; PAZOPANIB; RANITIDINE;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALOPECIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOOD SAMPLING; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CONTINUOUS INFUSION; DEPIGMENTATION; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG POTENTIATION; DRUG SAFETY; DYSGEUSIA; EPISTAXIS; ESOPHAGUS VARICES; FATIGUE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEMATEMESIS; HOT FLUSH; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; HYPOPIGMENTATION; HYPOTHYROIDISM; LIVER TOXICITY; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PORTAL HYPERTENSION; PRIORITY JOURNAL; QT PROLONGATION; SIDE EFFECT; SOLID TUMOR; STEADY STATE; THROMBOCYTOPENIA; UPPER ABDOMINAL PAIN; URINARY TRACT INFECTION; VISUAL DISORDER; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS; PACLITAXEL; PYRIMIDINES; SULFONAMIDES; SURVIVAL RATE; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

EID: 78650992277     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2010-0095     Document Type: Article

References (16)

1. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82:4-6.
2. Sternberg CN, Davis ID, Mardiak J et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial. J Clin Oncol 28:1061-1068.
3. Kumar R, Knick VB, Rudolph SK et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 2007;6:2012-2021.
4. Harris PA, Boloor A, Cheung M et al. Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor. J Med Chem 2008;51:4632-4640.
5. Hurwitz HI, Dowlati A, Saini S et al. Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res 2009;15:4220-4227.
6. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
7. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-2550.
8. Shaked Y, Henke E, Roodhart JM et al. Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: Implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell 2008;14:263-273.
9. Lau D, Guo L, Gandara D et al. Is inhibition of cancer angiogenesis and growth by paclitaxel schedule dependent? Anticancer Drugs 2004;15:871-875.
10. Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666-2676.
11. Monsarrat B, Royer I, Wright M et al. Biotransformation of taxoids by human cytochromes P450: Structure-activity relationship. Bull Cancer 1997; 84:125-133.
12. Desai PB, Duan JZ, Zhu YW, et al. Human liver microsomal metabolism of paclitaxel and drug interactions. Eur J Drug Metab Pharmacokinet 1998; 23:417-424.
13. Heath EI, Chiorean EG, Sweeney CJ et al. A phase I study of the pharmacokinetic and safety profiles of oral pazopanib with a high-fat or low-fat meal in patients with advanced solid tumors. Clin Pharmacol Ther 2010 Oct 27 [Epub ahead of print].
14. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
15. Marchetti P, Urien S, Cappellini GA et al. Weekly administration of paclitaxel: Theoretical and clinical basis. Crit Rev Oncol Hematol 2002; 44(suppl):S3-S13.
16. Mross K, Häring B, Holländer N et al. Comparison of 1-hour and 3-hours paclitaxel infusion pharmacokinetics: Results from a randomized trial. Onkologie 2002;25:503-508.